Risk assessment according to IPSS-M is superior to AML ELN risk classification in MDS/AML overlap patients defined by ICC. Huber S, Baer C, Hutter S, Dicker F, et al. Leukemia 2023;37:2138-2141.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Huber S, Baer C, Hutter S, Dicker F, et al. Risk assessment according to IPSS-M is superior to AML ELN risk classification in MDS/AML overlap patients defined by ICC. Leukemia 2023;37:2138-2141.
PMID: 37573403